LENZ Therapeutics (LENZ) Insider George Buys 22,100 Shares
Jeffrey George bought 22,100 shares of LENZ at $6.77 each on June 15, 2026, as part of a wave of insider purchases.
Reviewed by automated data checks against the source filing. How we make and check alerts
Jeffrey George bought 22,100 shares of LENZ Therapeutics, Inc. ($LENZ) on June 15, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $LENZ is down 12.2% after 1 week, down 24.7% after 1 month and down 50.7% to date (from the $6.63 close on Jun 15, 2026).
LENZ
LENZ Therapeutics, Inc.
Key Points
- Jeffrey George purchased 22,100 shares of LENZ at $6.77 each on June 15, 2026, contributing to a significant insider buying trend.
- LENZ Therapeutics, Inc. has a market cap of approximately $128.2 million and is focused on developing therapies for vision improvement.
- Analysts have varying opinions on LENZ, with a consensus price target of $24.00 and a mix of ratings from firms like Piper Sandler and HC Wainwright.
Get $LENZ trade alerts by text
We text you when insiders, Congress or big funds trade $LENZ. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated LENZ Therapeutics, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at LENZ Therapeutics, Inc.
Jeffrey George bought 22,100 shares of LENZ (LENZ) at a price of $6.77 each on June 15, 2026. This purchase comes as part of a broader trend, with several other insiders also making the same acquisition on the same day. Notably, L.P. Ra Capital Management, Kimberlee Drapkin, Shelley Thunen, James McCollum, Frederic Guerard, and Zachary Scheiner all bought 22,100 shares each, indicating a collective confidence in the company's future.
How LENZ Stock Has Traded
LENZ shares are currently trading at $6.77, which is near its 52-week low of $4.00. The stock has experienced significant fluctuations, making this insider buying particularly noteworthy. With the next earnings report scheduled for November 4, 2026, investors will be watching closely to see how the company performs.
Analysts Set New Price Targets
On July 7, 2026, HC Wainwright & Co. reiterated a "Buy" rating for LENZ with a price target of $38.00. Meanwhile, on August 12, 2026, Piper Sandler maintained a "Neutral" rating, lowering its target from $12.00 to $7.00. The average target price among analysts stands at $24.00, reflecting a mix of opinions on the company's potential.
About LENZ Therapeutics
LENZ Therapeutics, Inc. is a commercial pharmaceutical company focused on developing therapies to improve vision, particularly for conditions like presbyopia in adults. This recent wave of insider buying suggests that those closest to the company believe in its growth potential as it approaches its next earnings announcement.
What to Watch at LENZ
Investors should keep an eye on the upcoming earnings report on November 4, 2026. It's important to remember that insider transactions provide a glimpse into the confidence of those involved with the company, but they do not necessarily indicate future performance. The 13F filings reflect past positions and may not represent current holdings, so further insider activity could be insightful as events unfold.
Related Filing Alerts
Source: Jeffrey George's Form 4 filing on $LENZ (Jun 15, 2026). Find the original filing: LENZ Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts